Skip to content
Screener

Debt-to-equity at other companies

ALN
Alnylam PharmaceuticalsALNY
0.2×-0.9×
Septerna, Inc. logo
Septerna, Inc.SEPN
0.1×0.0×
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
0.0×
Regenxbio logo
RegenxbioRGNX
+0.6×
Opko Health logo
Opko HealthOPK
0.0×
Celcuity logo
CelcuityCELC
2.6×+1.4×

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$639.46M+54.6%
Enterprise value$407.46M+219%

Returns & leverage

See full
Return on equity-31.4%
Current ratio18.5×-4.4×

Where this comes from

Calculated from Tectonic Therapeutics’s reported figures.

Based on the most recent quarter.

The source filing: Tectonic Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212016

FAQ

What is Tectonic Therapeutics's debt-to-equity?
Tectonic Therapeutics (TECX) reported debt-to-equity of 0× in Q1 2026.
How has Tectonic Therapeutics's debt-to-equity changed year-over-year?
Tectonic Therapeutics's debt-to-equity increased by 144.8% year-over-year, from 0× to 0×.
What is the long-term trend for Tectonic Therapeutics's debt-to-equity?
Over 2 years (2021 to 2025), Tectonic Therapeutics's debt-to-equity has grown at a -74.4% compound annual growth rate (CAGR), from 0.1× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Tectonic Therapeutics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude